Taysha Gene Therapies PE Ratio 2020-2026 | TSHA
Current and historical p/e ratio for Taysha Gene Therapies (TSHA) from 2020 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Taysha Gene Therapies PE ratio as of May 19, 2026 is 0.00.
| Taysha Gene Therapies PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-05-20 | 5.49 | 0.00 | |
| 2026-03-31 | 4.47 | $-0.38 | 0.00 |
| 2025-12-31 | 5.50 | $-0.34 | 0.00 |
| 2025-09-30 | 3.27 | $-0.33 | 0.00 |
| 2025-06-30 | 2.31 | $-0.34 | 0.00 |
| 2025-03-31 | 1.39 | $-0.34 | 0.00 |
| 2024-12-31 | 1.73 | $-0.36 | 0.00 |
| 2024-09-30 | 2.01 | $0.34 | 5.91 |
| 2024-06-30 | 2.24 | $-0.49 | 0.00 |
| 2024-03-31 | 2.87 | $-0.78 | 0.00 |
| 2023-12-31 | 1.77 | $-0.96 | 0.00 |
| 2023-09-30 | 3.16 | $-2.55 | 0.00 |
| 2023-06-30 | 0.66 | $-2.27 | 0.00 |
| 2023-03-31 | 0.80 | $-2.74 | 0.00 |
| 2022-12-31 | 2.26 | $-3.78 | 0.00 |
| 2022-09-30 | 1.93 | $-4.15 | 0.00 |
| 2022-06-30 | 3.72 | $-4.85 | 0.00 |
| 2022-03-31 | 6.52 | $-5.09 | 0.00 |
| 2021-12-31 | 11.65 | $-4.64 | 0.00 |
| 2021-09-30 | 18.62 | $-2.98 | 0.00 |
| 2021-06-30 | 21.20 | $-2.91 | 0.00 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $1.290B | $0.010B |
| Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |